Belimumab (anti-B-cell-activating factor) and anifrolumab (anti-interferon alpha receptor-1) have been approved globally for treating SLE patients.5 Rituximab (anti-CD20) is recommended as an off-label treatment option for refractory, organ-threatening SLE.8 However, there is still a substantial proportion of patients failing to respond to available therapies, underscoring the urgent need for more effective therapies. Here, TNFSF13B is linked to systemic lupus erythematosus.